GenMark (GNMK) Looks 'Ready to Double', Says Cowen; Analyst Raises Rating to 'Outperform'
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
(Updated - September 16, 2016 10:24 AM EDT)
Cowen upgraded GenMark Diagnostics (NASDAQ: GNMK) from Market Perform to Outperform with a price target of $17. Analyst Doug Schenkel noted strong ePlex channel checks said he said the stock "looks ready to double."
"Recent channel checks suggest ePlex is performing robustly within early EU adopter sites, and US clinical trials are likely to commence shortly (if they haven't already). We've always liked the market opportunity, and after a long history of delays, ePlex finally appears ready to go," said Schenkel.
The analyst continued, "We downgraded GenMark to Market Perform in the Fall of 2015 (link) subsequent to a delay in ePlex timelines. Our concern was that management’s revised timelines (Q1:16 CE Mark and Q2:16 FDA submission) left little room for error. After a subsequent delay, ePlex timelines are now about in line with our assumptions at the time of our downgrade (Q3:16 CE Mark, Q1:17 US launch). About one year later, checks indicate that sample variability concerns are now addressed, and we have increased conviction in an early-2017 US ePlex launch."
Schenkel added, "We believe it is possible the FDA submission slips into early 2017, but any delay from here would be weeks, not months (no notable revenue impact). Even acknowledging the potential for a slight delay (possible, but not necessarily likely), as well as a likely equity financing over the next 12-18 months, we would begin accumulating a position in shares now while investor sentiment remains muted for reasons outlined below."
Shares of GenMark Diagnostics closed at $8.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- New Bill Suggests GSE Reform is Forthcoming (FNMA) (FMCC)
- Broadcom (AVGO) PT Raised to $215 at Oppenheimer
- UBS Raises Price Target on Selecta Biosciences (SELB) to $29
Create E-mail Alert Related CategoriesAnalyst Comments, Hot Comments, Hot Upgrades, Upgrades
Related EntitiesCowen & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!